Cargando…

Efficacy of autologous bone marrow mononuclear cell transplantation therapy in patients with refractory diabetic peripheral neuropathy

BACKGROUND: Owing to the multifactorial nature of the pathogenesis of diabetic peripheral neuropathy (DPN), conventional drug therapies have not been effective. The application of stem cells transplantation may be useful for the treatment of DPN. This study was designed to assess the safety and ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Mao, Hong, Wei, Wei, Fu, Xiu-Li, Dong, Jing-Jian, Lyu, Xiao-Yu, Jia, Ting, Tang, Yang, Zhao, Shi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6629317/
https://www.ncbi.nlm.nih.gov/pubmed/30628954
http://dx.doi.org/10.1097/CM9.0000000000000009
_version_ 1783435085162217472
author Mao, Hong
Wei, Wei
Fu, Xiu-Li
Dong, Jing-Jian
Lyu, Xiao-Yu
Jia, Ting
Tang, Yang
Zhao, Shi
author_facet Mao, Hong
Wei, Wei
Fu, Xiu-Li
Dong, Jing-Jian
Lyu, Xiao-Yu
Jia, Ting
Tang, Yang
Zhao, Shi
author_sort Mao, Hong
collection PubMed
description BACKGROUND: Owing to the multifactorial nature of the pathogenesis of diabetic peripheral neuropathy (DPN), conventional drug therapies have not been effective. The application of stem cells transplantation may be useful for the treatment of DPN. This study was designed to assess the safety and therapeutic effects of autologous bone marrow mononuclear cells (BMMNCs) transplantation on the treatment of refractory DPN. METHODS: One hundred and sixty-eight patients with refractory DPN were recruited and enrolled in the study. They received intramuscular injection of BMMNCs and followed at 1, 3, 6, 12, 18, 24, and 36 months after the transplantation. Clinical data, Toronto Clinical Scoring System (TCSS), and nerve conduction studies (NCSs) were compared before and after the transplantation. RESULTS: The signs and symptoms of neuropathy were significantly improved after BMMNCs transplantation. The values of the TCSS scores at 1 month (9.68 ± 2.49 vs. 12.55 ± 2.19, P < 0.001) and 3 months (8.47 ± 2.39 vs. 12.55 ± 2.19, P < 0.001) after the treatment reduced significantly compared with the baseline value. This decrement remained persistent until the end of the study. The conduction velocity and action potential and sensory nerves were significantly improved after transplantation (3 and 12 months after the treatment vs. the baseline: motor nerve conduction velocity, 40.24 ± 2.80 and 41.00 ± 2.22 m/s vs. 38.21 ± 2.28 m/s, P < 0.001; sensory nerve conduction velocity, 36.96 ± 2.26 and 39.15 ± 2.61 m/s vs. 40.41 ± 2.22 m/s, P < 0.001; compound muscle action potential, 4.67 ± 1.05 and 5.50 ± 1.20 μV vs. 5.68 ± 1.08 μV, P < 0.001; sensory nerve action potential, 4.29 ± 0.99 and 5.14 ± 1.26 μV vs. 5.41 ± 1.14 μV, P < 0.001). No adverse event associated with the treatment was observed during the follow-up period. CONCLUSIONS: Autologous transplantation of BMMNCs may be an effective and promising therapeutic strategy for the treatment of refractory DPN.
format Online
Article
Text
id pubmed-6629317
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-66293172019-07-22 Efficacy of autologous bone marrow mononuclear cell transplantation therapy in patients with refractory diabetic peripheral neuropathy Mao, Hong Wei, Wei Fu, Xiu-Li Dong, Jing-Jian Lyu, Xiao-Yu Jia, Ting Tang, Yang Zhao, Shi Chin Med J (Engl) Original Articles BACKGROUND: Owing to the multifactorial nature of the pathogenesis of diabetic peripheral neuropathy (DPN), conventional drug therapies have not been effective. The application of stem cells transplantation may be useful for the treatment of DPN. This study was designed to assess the safety and therapeutic effects of autologous bone marrow mononuclear cells (BMMNCs) transplantation on the treatment of refractory DPN. METHODS: One hundred and sixty-eight patients with refractory DPN were recruited and enrolled in the study. They received intramuscular injection of BMMNCs and followed at 1, 3, 6, 12, 18, 24, and 36 months after the transplantation. Clinical data, Toronto Clinical Scoring System (TCSS), and nerve conduction studies (NCSs) were compared before and after the transplantation. RESULTS: The signs and symptoms of neuropathy were significantly improved after BMMNCs transplantation. The values of the TCSS scores at 1 month (9.68 ± 2.49 vs. 12.55 ± 2.19, P < 0.001) and 3 months (8.47 ± 2.39 vs. 12.55 ± 2.19, P < 0.001) after the treatment reduced significantly compared with the baseline value. This decrement remained persistent until the end of the study. The conduction velocity and action potential and sensory nerves were significantly improved after transplantation (3 and 12 months after the treatment vs. the baseline: motor nerve conduction velocity, 40.24 ± 2.80 and 41.00 ± 2.22 m/s vs. 38.21 ± 2.28 m/s, P < 0.001; sensory nerve conduction velocity, 36.96 ± 2.26 and 39.15 ± 2.61 m/s vs. 40.41 ± 2.22 m/s, P < 0.001; compound muscle action potential, 4.67 ± 1.05 and 5.50 ± 1.20 μV vs. 5.68 ± 1.08 μV, P < 0.001; sensory nerve action potential, 4.29 ± 0.99 and 5.14 ± 1.26 μV vs. 5.41 ± 1.14 μV, P < 0.001). No adverse event associated with the treatment was observed during the follow-up period. CONCLUSIONS: Autologous transplantation of BMMNCs may be an effective and promising therapeutic strategy for the treatment of refractory DPN. Wolters Kluwer Health 2019-01-05 2019-01-05 /pmc/articles/PMC6629317/ /pubmed/30628954 http://dx.doi.org/10.1097/CM9.0000000000000009 Text en Copyright © 2018 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0
spellingShingle Original Articles
Mao, Hong
Wei, Wei
Fu, Xiu-Li
Dong, Jing-Jian
Lyu, Xiao-Yu
Jia, Ting
Tang, Yang
Zhao, Shi
Efficacy of autologous bone marrow mononuclear cell transplantation therapy in patients with refractory diabetic peripheral neuropathy
title Efficacy of autologous bone marrow mononuclear cell transplantation therapy in patients with refractory diabetic peripheral neuropathy
title_full Efficacy of autologous bone marrow mononuclear cell transplantation therapy in patients with refractory diabetic peripheral neuropathy
title_fullStr Efficacy of autologous bone marrow mononuclear cell transplantation therapy in patients with refractory diabetic peripheral neuropathy
title_full_unstemmed Efficacy of autologous bone marrow mononuclear cell transplantation therapy in patients with refractory diabetic peripheral neuropathy
title_short Efficacy of autologous bone marrow mononuclear cell transplantation therapy in patients with refractory diabetic peripheral neuropathy
title_sort efficacy of autologous bone marrow mononuclear cell transplantation therapy in patients with refractory diabetic peripheral neuropathy
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6629317/
https://www.ncbi.nlm.nih.gov/pubmed/30628954
http://dx.doi.org/10.1097/CM9.0000000000000009
work_keys_str_mv AT maohong efficacyofautologousbonemarrowmononuclearcelltransplantationtherapyinpatientswithrefractorydiabeticperipheralneuropathy
AT weiwei efficacyofautologousbonemarrowmononuclearcelltransplantationtherapyinpatientswithrefractorydiabeticperipheralneuropathy
AT fuxiuli efficacyofautologousbonemarrowmononuclearcelltransplantationtherapyinpatientswithrefractorydiabeticperipheralneuropathy
AT dongjingjian efficacyofautologousbonemarrowmononuclearcelltransplantationtherapyinpatientswithrefractorydiabeticperipheralneuropathy
AT lyuxiaoyu efficacyofautologousbonemarrowmononuclearcelltransplantationtherapyinpatientswithrefractorydiabeticperipheralneuropathy
AT jiating efficacyofautologousbonemarrowmononuclearcelltransplantationtherapyinpatientswithrefractorydiabeticperipheralneuropathy
AT tangyang efficacyofautologousbonemarrowmononuclearcelltransplantationtherapyinpatientswithrefractorydiabeticperipheralneuropathy
AT zhaoshi efficacyofautologousbonemarrowmononuclearcelltransplantationtherapyinpatientswithrefractorydiabeticperipheralneuropathy